EVOLVE
Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events
Patient / Population Intervention / Exposure Comparison Outcome
In 3,883 haemodialysis patients with secondary hyperparathyroidism, cinacalcet did not significantly reduce death or cardiovascular events compared with placebo.
N
3,883
Design
Double-blind RCT
Endpoint
Composite of death or first non-fatal cardiovascular event
Relevance
2
Result48.2% vs 49.2%; HR 0.93 (95% CI 0.85–1.02; p=0.11); age-adjusted HR 0.88.
Chertow GM, et al. N Engl J Med. 2012;367(26):2482-2494. 10.1056/NEJMoa1205624
Discussion & critique
No universal CV benefit; high dropout and crossover; cinacalcet is now used selectively in refractory disease.